Nkarta EBITDA Margin 2020-2024 | NKTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Nkarta ebitda margin from 2020 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Nkarta EBITDA Margin 2020-2024 | NKTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Nkarta ebitda margin from 2020 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.9B
Regeneron Pharmaceuticals (REGN)	$125.5B
Vertex Pharmaceuticals (VRTX)	$122.4B
Gilead Sciences (GILD)	$104.4B
Bristol Myers Squibb (BMY)	$100.8B
CSL (CSLLY)	$96.8B
GSK (GSK)	$87.9B
Alnylam Pharmaceuticals (ALNY)	$35.1B
Argenex SE (ARGX)	$31.6B
Biogen (BIIB)	$28.8B
BioNTech SE (BNTX)	$27.5B
Moderna (MRNA)	$26.9B
Illumina (ILMN)	$20.9B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.3B
BioMarin Pharmaceutical (BMRN)	$13.5B
Vaxcyte (PCVX)	$13B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.6B
Insmed (INSM)	$12.5B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.7B
Repligen (RGEN)	$8B
Halozyme Therapeutics (HALO)	$7.9B
Intra-Cellular Therapies (ITCI)	$7.9B